Psilocybin for Depression: Payers Weigh Risks, Rewards, and Readiness

Treatment-resistant depression, or TRD, affects people who don't get better after trying at least two different antidepressants. These folks often deal with worse quality of life and higher medical bills. That's why some experts are looking at new options like psilocybin, the active compound in magic mushrooms.

In March 2026, a group of health plan leaders and mental health experts got together online to talk about how insurance companies can better handle TRD. They wanted to figure out smart ways to cover treatments that actually work.

The big problem? There's still not enough proof that psilocybin works better than other treatments. Payers say they need more data. They want to know who should take it, how it compares to existing drugs, and if it's worth the cost.

Another major issue is finding enough trained doctors and therapists. Psilocybin can't just be handed out. It needs careful supervision during and after use. That means health plans need to build up their behavioral health teams fast.

So what can insurers do now? Experts suggest educating staff, working with mental health providers, and making sure networks are ready. The goal is simple: help patients get real relief without wasting time or money.